Medication info
Glimez Tablet (Glimepiride)

Glimez Tablet (Glimepiride)

Prescription medicationTabletOral
Ingredient · strength
Glimepiride›2mg / 1 tablet
Manufacturer / importer
iWorld Pharmaceutical Co., Ltd.
Appearance
Green, oblong tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200402490 · Notified 2004.05.07 · Insurance code 669604310

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Adjust the dose individually for each patient. Swallow whole without chewing, with at least 1/2 cup of water. This drug is administered orally once daily. This drug should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this drug. 1. Monotherapy 1) Initial dose and dose determination For patients who have not previously received medication, start treatment with glimepiride 1 mg once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, there is little additional benefit with doses above 4 mg, but some patients showed better metabolic control when the dose was increased to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider use in combination with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control improves during treatment, the patient's requirement for this drug may decrease. Therefore, dose reduction or discontinuation of this drug may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral hypoglycemic agent to this drug There is no exact dose equivalence between this drug and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this drug, it is advisable to follow the method described under Initial dose. That is, start treatment with 1 mg daily and adjust the dose at intervals of 1 ~ 2 weeks. The potency and duration of action of the previously administered drug should be taken into consideration. 4) Dose adjustment While taking this drug, blood glucose and/or urine glucose levels should be measured regularly, and regular measurement of glycated hemoglobin (HbA1c) levels is also recommended. In general, hypoglycemia is promptly corrected by immediate intake of sugar. Hypoglycemia may recur even after it has been successfully managed initially during treatment with sulfonylureas. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy of this drug with insulin is used in patients with secondary failure, and is used when fasting blood glucose (FBG) exceeds 150 mg/dL. This drug is administered at a dose of 8 mg once daily with the first meal, while insulin is started at a low dose and increased at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. The insulin dose should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this drug, addition of metformin may be considered. Clinical data have been published on combination therapy of metformin with other sulfonylureas such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this drug is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each drug. However, efforts should be made to determine the minimum effective dose of each drug for blood glucose control. There is a risk of hypoglycemia with concomitant administration of this drug and metformin, and the risk may increase. Appropriate caution should be exercised.

Ingredients

Manufacturer
iWorld Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used together with dietary management and exercise therapy to improve blood sugar control in patients with type 2 diabetes. It can be administered as monotherapy and may be used in combination with insulin if blood sugar control is insufficient with oral hypoglycemic agents. Additionally, it is used in combination with metformin when treatment with sulfonylureas or metformin alone is insufficient. This medication is used effectively to aid blood sugar control alongside various therapeutic methods.

How to take

Adult dose

Adjust the dose individually for each patient. Swallow whole without chewing, with at least 1/2 cup of water. This drug is administered orally once daily. This drug should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this drug. 1. Monotherapy 1) Initial dose and dose determination For patients who have not previously received medication, start treatment with glimepiride 1 mg once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, there is little additional benefit with doses above 4 mg, but some patients showed better metabolic control when the dose was increased to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider use in combination with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control improves during treatment, the patient's requirement for this drug may decrease. Therefore, dose reduction or discontinuation of this drug may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral hypoglycemic agent to this drug There is no exact dose equivalence between this drug and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this drug, it is advisable to follow the method described under Initial dose. That is, start treatment with 1 mg daily and adjust the dose at intervals of 1 ~ 2 weeks. The potency and duration of action of the previously administered drug should be taken into consideration. 4) Dose adjustment While taking this drug, blood glucose and/or urine glucose levels should be measured regularly, and regular measurement of glycated hemoglobin (HbA1c) levels is also recommended. In general, hypoglycemia is promptly corrected by immediate intake of sugar. Hypoglycemia may recur even after it has been successfully managed initially during treatment with sulfonylureas. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy of this drug with insulin is used in patients with secondary failure, and is used when fasting blood glucose (FBG) exceeds 150 mg/dL. This drug is administered at a dose of 8 mg once daily with the first meal, while insulin is started at a low dose and increased at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. The insulin dose should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this drug, addition of metformin may be considered. Clinical data have been published on combination therapy of metformin with other sulfonylureas such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this drug is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each drug. However, efforts should be made to determine the minimum effective dose of each drug for blood glucose control. There is a risk of hypoglycemia with concomitant administration of this drug and metformin, and the risk may increase. Appropriate caution should be exercised.

Precautions

This medication should not be used in patients with insulin-dependent type 1 diabetes, diabetic ketoacidosis, or coma. It should also not be administered to individuals allergic to this drug, its components, or drugs in the sulfonylurea or sulfonamide class. There is no experience with use in patients with severe liver or kidney dysfunction, and in such cases, switching to insulin treatment is recommended. Women who are pregnant, may become pregnant, or are breastfeeding should not take this medication. Insulin therapy is necessary for patients with severe infections, pre- and post-surgery, or severe trauma, and caution should be exercised in patients with gastrointestinal disorders where food absorption is impaired due to the risk of hypoglycemia. Additionally, this medication contains lactose, so it should not be administered to patients with lactose intolerance or related genetic disorders. During the first week of administration, there is a higher risk of hypoglycemia, so close monitoring is particularly important, especially for elderly patients, those with poor nutritional status or irregular eating habits, patients who frequently consume alcohol, those with impaired liver or kidney functions, and patients with other endocrine disorders. Moreover, there may be potential interactions when taken with other medications, necessitating dosage adjustments. This medication has a strong hypoglycemic effect and may cause hypoglycemia; symptoms of hypoglycemia can include headache, severe hunger, nausea, fatigue, confusion, drowsiness, decreased consciousness, etc. Rare side effects reported include blurred vision, gastrointestinal disturbances, liver function abnormalities, blood disorders, and allergic reactions, and severe cases require immediate notification to a physician. It is essential to maintain regular meals, exercise, and weight control when taking this medication, and patients should always carry sugar to respond quickly in case of hypoglycemia. In times of stress, surgery, or infection, switching to insulin therapy may be necessary. When taken with other medications, blood sugar-lowering effects may be increased or decreased, so it is essential to inform healthcare providers about all medications being taken. Particularly, there may be interactions with beta-blockers, some antibiotics, and steroids. Women who are pregnant or nursing should avoid this medication as it could harm the fetus or newborn and should be substituted with insulin therapy if necessary. Safety and efficacy have not been established in pediatric patients under 18 years of age. In elderly patients, caution is required for dose adjustments due to possible reduced kidney function. In cases of overdose, severe hypoglycemia may occur and immediate emergency treatment is required, which could involve inducing vomiting, gastric lavage, or administering glucose intravenously. This medication should be stored out of reach of children and in its original container for safety.

Side effects

  • Hypoglycemia
  • headache
  • severe hunger
  • nausea
  • vomiting
  • fatigue
  • sleep
  • sleep disorders
  • anxiety
  • aggression
Show 68 more
  • decreased concentration
  • decreased agility or drive
  • depression
  • confusion
  • speech difficulties
  • aphasia
  • visual impairment
  • tremors
  • incomplete paralysis
  • sensory disturbances
  • dizziness
  • weakness
  • loss of self-control
  • temporary mental confusion
  • brain convulsions
  • drowsiness
  • loss of consciousness
  • coma
  • shallow breathing
  • bradycardia
  • sweating
  • cold and clammy skin
  • tachycardia
  • hypertension
  • palpitations
  • angina
  • deep vein thrombosis
  • blurred vision
  • fullness in the upper abdomen
  • pressure sensation
  • abdominal pain
  • diarrhea
  • increased liver enzymes
  • liver dysfunction
  • bile secretion disorder
  • jaundice
  • hepatitis
  • thrombocytopenia
  • leukopenia
  • hemolytic anemia
  • erythropenia
  • granulocytopenia
  • agranulocytosis
  • pancytopenia
  • itching
  • hives
  • rash
  • dyspnea
  • hypotension
  • shock
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • allergic vasculitis
  • photosensitivity reactions of the skin
  • decrease in serum sodium concentration
  • taste disorder
  • hair loss
  • weight gain
  • dizziness
  • liver dysfunction
  • abdominal pain
  • arthralgia
  • dyspepsia
  • facial swelling
  • erectile dysfunction
  • facial flushing
  • gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from exposure to air and moisture. It is important to maintain a storage temperature between 1°C and 30°C at room temperature.

Appearance and packaging

Appearance

Green, oblong tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.